Cost-effectiveness of HCV testing strategies for hepatitis C elimination in general population in China
10.3760/cma.j.cn112338-20230908-00140
- VernacularTitle:我国消除丙型肝炎的普通人群HCV检测策略的成本效果分析
- Author:
Pengcheng LIU
1
;
Di XU
;
Guowei DING
;
Liang ZHAO
;
Jiejun YU
;
Zhongfu LIU
;
Jian LI
Author Information
1. 中国疾病预防控制中心性病艾滋病预防控制中心，北京 102206
- Keywords:
Hepatitis C;
General population;
Screening;
Cost-effectiveness;
Markov model
- From:
Chinese Journal of Epidemiology
2024;45(3):464-472
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the cost-effectiveness of hepatitis C screening in general population in China, and find the age group in which hepatitis C screening can achieve the best cost-effectiveness.Methods:A decision-Markov model was constructed by using software TreeAge pro 2019 to simulate the outcomes of hepatitis C disease pregression of 100 000 persons aged 20-59 years. The cost-effectiveness of the strategies were evaluated from societal perspectives by using incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB). One-way sensitivity analysis and probability sensitivity analysis were used to evaluate the uncertainty of parameters and model.Results:Hepatitis C screening was cost-effective in people aged 20- 59 years and the cost effectiveness was best in age group 40-49 years. Compared with non-screening strategy of hepatitis C in people aged 20-59 years, the incremental cost was 161.24 yuan, the incremental utility was 0.003 6 quality adjusted life years (QALYs)/per person, ICER was 45 197.26 yuan/QALY, ICER was less than the willing payment threshold. The ICER and NMB in all age groups were 42 055.06-53 249.43 yuan/QALY and 96.52-169.86 yuan/per person. Hepatitis C screening in people aged 40-49 years had the best cost-effectiveness. The results of one-way sensitivity analysis showed that the discount rate, anti-HCV detection cost, anti-HCV infection rate and the cost of direct antiviral agents were the main factors influencing economic evaluation. The results of the probability sensitivity analysis indicated that the model analysis was stable.Conclusions:Implementing hepatitis C screening based on medical institutions is cost-effective in people aged 20- 59 years, especially in those aged 40-49 years. Implementing the HCV screening strategy of be willing to test as far as possible in general population can reduce hepatitis C disease burden in China.
